Similar articles

• Conflicting results on the efficacy of enteral nutrition during infliximab maintenance therapy for Crohn's disease are correct.

  Chiba M, Tsuji T, Komatsu M. Chiba M, et al. Dig Dis Sci. 2014 Jan;59(1):227-8. doi: 10.1007/s10620-013-2954-9. Epub 2013 Nov 27. Dig Dis Sci. 2014. PMID: 24282058 No abstract available.
• Efficacy of enteral nutrition during infliximab maintenance therapy in patients with Crohn's disease.

  Yamamoto T, Shiraki M. Yamamoto T, et al. Dig Dis Sci. 2013 Jun;58(6):1802-3. doi: 10.1007/s10620-012-2497-5. Epub 2012 Nov 30. Dig Dis Sci. 2013. PMID: 23196358 No abstract available.
• [Drug therapy and nutrition therapy of a young patient with Crohn disease].

  Verkasalo M. Verkasalo M. Duodecim. 2003;119(7):617-24. Duodecim. 2003. PMID: 12762201 Review. Finnish. No abstract available.
• Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.

  Bauditz J, Lochs H, Schreiber S. Bauditz J, et al. N Engl J Med. 1998 Jan 29;338(5):334. doi: 10.1056/NEJM199801293380515. N Engl J Med. 1998. PMID: 9446035 No abstract available.
• [Progress in diagnosis and treatment of Crohn disease].

  Yao T. Yao T. Nihon Naika Gakkai Zasshi. 2002 Mar 20;91 Suppl:38-42. Nihon Naika Gakkai Zasshi. 2002. PMID: 11989261 Review. Japanese. No abstract available.